Companies Forge Huntington’s Disease Therapeutic and Companion Biomarker Collaboration
Published: Friday, February 22, 2013 Last Updated: Friday, February 22, 2013
KineMed, Isis and CHDI collaborate to advance therapeutic development for Huntington’s disease and develop novel biomarkers for pre-clinical and clinical use in drug development and therapeutic monitoring.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.